When did ALZAMEND NEURO INC (ALZN) report earnings last quarter?
ALZAMEND NEURO INC (ALZN) last reported earnings on 3/11/2026.
NASDAQ:ALZN • US02262M6057
Past quarterly earnings results for ALZAMEND NEURO INC (ALZN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2026 | -0.58 | -1.96 | 70.46% | 66.08% | - | - | ||
| Q2 2026 | -0.30 | -1.99 | 84.96% | 91.23% | - | - | ||
| Q1 2026 | -1.28 | -0.70 | -81.87% | 88.62% | - | - | ||
| Q4 2025 | -3.44 | - | 97.13% | - | - | |||
| Q3 2025 | -1.71 | -3.26 | 47.53% | 95.00% | - | - | ||
| Q2 2025 | -3.42 | -3.49 | 1.96% | 91.36% | - | - | ||
| Q1 2025 | -11.25 | -21.85 | 48.51% | 79.17% | - | - | ||
| Q4 2024 | -120.15 | -25.25 | -375.94% | -196.67% | - | - | ||
| Q3 2024 | -34.20 | -29.84 | -14.63% | 57.78% | - | - | ||
| Q2 2024 | -39.60 | -61.97 | 36.09% | 2.22% | - | - | ||
| Q1 2024 | -54.00 | -48.20 | -12.04% | -33.33% | - | - | ||
| Q4 2023 | -40.50 | -61.97 | 34.64% | 25.00% | - | - | ||
| Q3 2023 | -81.00 | -55.08 | -47.06% | -100.00% | - | - | ||
| Q2 2023 | -40.50 | -55.08 | 26.47% | 25.00% | - | - | ||
| Q1 2023 | -40.50 | -96.39 | 57.98% | - | - | - | ||
| Q4 2022 | -54.00 | -41.31 | -30.72% | - | - | - | ||
| Q3 2022 | -40.50 | -27.54 | -47.06% | - | - | - | ||
| Q2 2022 | -54.00 | -34.43 | -56.86% | - | - | - | ||
| Q1 2022 | - | - | - | - | ||||
| Q4 2021 | - | - | - | - | ||||
| Q3 2021 | - | - | - | - | ||||
| Q2 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - |
Notes
ALZAMEND NEURO INC (ALZN) last reported earnings on 3/11/2026.
ALZAMEND NEURO INC (ALZN) beat EPS estimates and missed revenue estimates in the most recent quarter.